150 related articles for article (PubMed ID: 34876311)
1. The iPSC perspective on schizophrenia.
Räsänen N; Tiihonen J; Koskuvi M; Lehtonen Š; Koistinaho J
Trends Neurosci; 2022 Jan; 45(1):8-26. PubMed ID: 34876311
[TBL] [Abstract][Full Text] [Related]
2. Application of induced pluripotent stem cells to understand neurobiological basis of bipolar disorder and schizophrenia.
Liu YN; Lu SY; Yao J
Psychiatry Clin Neurosci; 2017 Sep; 71(9):579-599. PubMed ID: 28393474
[TBL] [Abstract][Full Text] [Related]
3. Neuronal Differentiation of Induced Pluripotent Stem Cells from Schizophrenia Patients in Two-Dimensional and in Three-Dimensional Cultures Reveals Increased Expression of the Kv4.2 Subunit DPP6 That Contributes to Decreased Neuronal Activity.
Naujock M; Speidel A; Fischer S; Kizner V; Dorner-Ciossek C; Gillardon F
Stem Cells Dev; 2020 Dec; 29(24):1577-1587. PubMed ID: 33143549
[TBL] [Abstract][Full Text] [Related]
4. Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models.
Perrottelli A; Marzocchi FF; Caporusso E; Giordano GM; Giuliani L; Melillo A; Pezzella P; Bucci P; Mucci A; Galderisi S
J Psychiatry Neurosci; 2024; 49(2):E109-E125. PubMed ID: 38490647
[TBL] [Abstract][Full Text] [Related]
5. Investigation of de novo mutations in a schizophrenia case-parent trio by induced pluripotent stem cell-based in vitro disease modeling: convergence of schizophrenia- and autism-related cellular phenotypes.
Hathy E; Szabó E; Varga N; Erdei Z; Tordai C; Czehlár B; Baradits M; Jezsó B; Koller J; Nagy L; Molnár MJ; Homolya L; Nemoda Z; Apáti Á; Réthelyi JM
Stem Cell Res Ther; 2020 Nov; 11(1):504. PubMed ID: 33246498
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological studies using iPSC-derived neurons from patients with schizophrenia].
Nakazawa T
Nihon Yakurigaku Zasshi; 2021; 156(4):220-223. PubMed ID: 34193699
[TBL] [Abstract][Full Text] [Related]
7. Contribution of induced pluripotent stem cell technologies to the understanding of cellular phenotypes in schizophrenia.
Balan S; Toyoshima M; Yoshikawa T
Neurobiol Dis; 2019 Nov; 131():104162. PubMed ID: 29729395
[TBL] [Abstract][Full Text] [Related]
8. Modeling schizophrenia pathogenesis using patient-derived induced pluripotent stem cells (iPSCs).
Noh H; Shao Z; Coyle JT; Chung S
Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2382-2387. PubMed ID: 28668333
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic Landscape and Functional Characterization of Induced Pluripotent Stem Cell-Derived Cerebral Organoids in Schizophrenia.
Kathuria A; Lopez-Lengowski K; Jagtap SS; McPhie D; Perlis RH; Cohen BM; Karmacharya R
JAMA Psychiatry; 2020 Jul; 77(7):745-754. PubMed ID: 32186681
[TBL] [Abstract][Full Text] [Related]
10. hVGAT-mCherry: A novel molecular tool for analysis of GABAergic neurons derived from human pluripotent stem cells.
DeRosa BA; Belle KC; Thomas BJ; Cukier HN; Pericak-Vance MA; Vance JM; Dykxhoorn DM
Mol Cell Neurosci; 2015 Sep; 68():244-57. PubMed ID: 26284979
[TBL] [Abstract][Full Text] [Related]
11. A dangerous method? The use of induced pluripotent stem cells as a model for schizophrenia.
Jacobs BM
Schizophr Res; 2015 Oct; 168(1-2):563-8. PubMed ID: 26194993
[TBL] [Abstract][Full Text] [Related]
12. Proteomic signatures of schizophrenia-sourced iPSC-derived neural cells and brain organoids are similar to patients' postmortem brains.
Nascimento JM; Saia-Cereda VM; Zuccoli GS; Reis-de-Oliveira G; Carregari VC; Smith BJ; Rehen SK; Martins-de-Souza D
Cell Biosci; 2022 Dec; 12(1):189. PubMed ID: 36451159
[TBL] [Abstract][Full Text] [Related]
13. A time course analysis of the electrophysiological properties of neurons differentiated from human induced pluripotent stem cells (iPSCs).
Prè D; Nestor MW; Sproul AA; Jacob S; Koppensteiner P; Chinchalongporn V; Zimmer M; Yamamoto A; Noggle SA; Arancio O
PLoS One; 2014; 9(7):e103418. PubMed ID: 25072157
[TBL] [Abstract][Full Text] [Related]
14. Modeling Psychiatric Diseases with Induced Pluripotent Stem Cells.
van Hugte E; Nadif Kasri N
Adv Exp Med Biol; 2019; 1192():297-312. PubMed ID: 31705501
[TBL] [Abstract][Full Text] [Related]
15. Modeling Schizophrenia In Vitro: Challenges and Insights on Studying Brain Cells.
Brandão-Teles C; Zuccoli GS; Smith BJ; Vieira GM; Crunfli F
Adv Exp Med Biol; 2022; 1400():35-51. PubMed ID: 35930224
[TBL] [Abstract][Full Text] [Related]
16. Current advancements of modelling schizophrenia using patient-derived induced pluripotent stem cells.
Dubonyte U; Asenjo-Martinez A; Werge T; Lage K; Kirkeby A
Acta Neuropathol Commun; 2022 Dec; 10(1):183. PubMed ID: 36527106
[TBL] [Abstract][Full Text] [Related]
17. Induced Pluripotent Stem Cells in Psychiatry: An Overview and Critical Perspective.
De Los Angeles A; Fernando MB; Hall NAL; Brennand KJ; Harrison PJ; Maher BJ; Weinberger DR; Tunbridge EM
Biol Psychiatry; 2021 Sep; 90(6):362-372. PubMed ID: 34176589
[TBL] [Abstract][Full Text] [Related]
18. Developmental excitation-inhibition imbalance underlying psychoses revealed by single-cell analyses of discordant twins-derived cerebral organoids.
Sawada T; Chater TE; Sasagawa Y; Yoshimura M; Fujimori-Tonou N; Tanaka K; Benjamin KJM; Paquola ACM; Erwin JA; Goda Y; Nikaido I; Kato T
Mol Psychiatry; 2020 Nov; 25(11):2695-2711. PubMed ID: 32764691
[TBL] [Abstract][Full Text] [Related]
19. Is the time right for in vitro neurotoxicity testing using human iPSC-derived neurons?
Tukker AM; de Groot MW; Wijnolts FM; Kasteel EE; Hondebrink L; Westerink RH
ALTEX; 2016; 33(3):261-71. PubMed ID: 27010910
[TBL] [Abstract][Full Text] [Related]
20. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
